NCT04979520View on ClinicalTrials.gov

Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

August 5, 2021

Primary Completion Date

July 25, 2022

Study Completion Date

July 25, 2022

Conditions
Hidradenitis SuppurativaAcne Inversa
Interventions
DRUG

Brodalumab

Subcutaneously Brodalumab/Siliq, 210mg/1.5ml once a week

Trial Locations (1)

10065

The Rockefeller University, New York

All Listed Sponsors
lead

Rockefeller University

OTHER

NCT04979520 - Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa | Biotech Hunter | Biotech Hunter